t
Tissue Regenix Group plc will announce its interim results for the six months ended 30 June 2023 on Tuesday, 5 September 2023. Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online investor presentation via the Investor Meet Company platform at 4:30 pm on Tuesday, 5 September 2023.
| Date | 21 Aug 2023 |
| Time | 07:00:05 |
| Category | Results |
| ID | 8235J |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
Notice of interim results
Investor presentation
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, confirms that it will annonce its interim results for the six months ended 30 June 2023 on Tuesday 5 September 2023.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the interim results via the Investor Meet Company platform at 4.30pm on Tuesday 5 September 2023. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here: https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
Investors who already follow Tissue Regenix on the Investor Meet Company platform will be de facto invited.
For more information:
|
Tissue Regenix Group plc |
||
|
David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
|
|
finnCap Ltd (Nominated Adviser and Broker) |
|
|
|
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance |
|
|
|
Nigel Birks/Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
|
Alice Woodings/Lianne Applegarth |
||
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.